BBlogFlow

Big Pharma's Big Brand: Regeneron's science-driven communications approach - Fierce Pharma

·Sep 29, 2026
Source: Fierce Pharma
Read the original article

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email

This article is an excerpt. To read the full content, visit the original source. Fierce Pharma

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

World Mental Health Day: Regeneron ISEF finalists explore big questions - Society for Science

Finnegan Sommer and Olutayo Oyewusi are the creators of TheraBee. Today, October 10, is World Mental Health Day, and with it, an opportunity to shed light on the quiet struggles and private resilience of the millions globally affected by mental health challenges. This year’s theme,  “Lived Experiences Heard: Real Voices, Real Change” Emphasizes the importance of listening to those experiences. In that spirit of empathy and action, we highlight five projects by recent Regeneron International Science and Engineering Fair (ISEF) finalists using STEM to explore questions across the spectrum of mental health research.

Society for Science·

Integrating hippopotamus optimization algorithm into machine learning frameworks for predicting suspended sediment concentrations - Nature

ORCID: orcid.org/0000-0001-8061-88361, Yaser Mehri2, Ali Abdolrazaq Sabbar3, Mohammad Javad Nahvinia3 & … Mohammad Hosein Omid2 We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.

Nature·

Development of a human respiratory tract effector cell-mediated antiviral assay using blood and airway immune cells from individuals previously hospitalised with COVID-19 - Nature

AcknowledgementsWe would like to thank Prof Alex Sigal (African Health Research Institute, South Africa) for providing the H1299 ACE-2 cell line used in the study. We thank the patients and their families for making this study possible. FundingResearch reported in this publication was supported by the South African Medical Research Council (SA MRC; grant number: 6803/CO AP 2021) with funds received from the Department of Science and Innovation. The content and findings reported/illustrated are the sole deduction, view and responsibility of the researcher and do not reflect the official position and sentiments of the SA MRC.

Nature·